News
Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...
Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...
In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...
Though Alzheimer's disease is often described as a buildup of proteins in the brain in the form of plaques and tangles, a new ...
10d
Study Finds on MSNGame-Changing Alzheimer’s Blood Test Could Eliminate Need For Brain ScansDiscover the breakthrough Alzheimer's test that measures tau tangles in blood, simplifying Alzheimer's diagnosis and ...
Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.
Age-related neurodegenerative disorders — motor neuron diseases, demyelinating diseases, Alzheimer’s disease, and other proteinopathies — are at an ‘inflection point.’ ...
11h
France 24 on MSNFormer France star Chabal says he has 'no memories' of rugby careerFormer France international Sebastien Chabal has said he has "no memories" from his international rugby career, potentially ...
GETTING your body moving is a key way to keep dementia at bay. But lowering your risk of the brain-robbing disease might not ...
BOSTON - NeuroNOS, a subsidiary of Beyond Air (NASDAQ:XAIR), has made a significant breakthrough in Alzheimer’s disease (AD) research, as detailed in a recent publication in the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results